论文部分内容阅读
目的探讨降钙素受体(calcitonin receptor CTR)在骨巨细胞瘤的表达情况及其与肿瘤预后的关系。方法对经过Jaffe病理分级的42例骨巨细胞瘤患者石蜡切片进行免疫组化S-P检测CTR表达水平,以12例骨软骨瘤为对照组,术后随访3～10年,并对结果进行统计学分析。结果①CTR在骨巨细胞瘤中阳性率81.0%,在骨软骨瘤中阳性率16.7%,二者差异有统计学意义(P<0.05);②42例骨巨细胞瘤患者中,复发17例,复发率40.5%;③复发组CTR阳性率64.7%,未复发组CTR阳性率92.6%,二者差异有统计学意义(P<0.05);④降钙素受体在JaffeⅠ级、Ⅱ级、Ⅲ级中阳性率分别为85.8%、75.0%、83.3%,三者之间差异无统计学意义(P>0.05)。结论 CTR在骨巨细胞瘤中高表达,有助于评估骨巨细胞瘤的预后。
Objective To investigate the expression of calcitonin receptor (CTR) in giant cell tumor of bone and its relationship with tumor prognosis. Methods Paraffin sections of 42 giant cell tumor patients with Jaffe pathological grading were examined by immunohistochemistry. The expression of CTR was detected by SP in 12 cases of osteochondroma. The patients were followed up for 3 to 10 years. The results were statistically analyzed analysis. Results ① The positive rate of CTR was 81.0% in giant cell tumor of bone and 16.7% in osteochondroma, the difference was statistically significant (P <0.05); ② Among the 42 cases of giant cell tumor of bone, 17 cases were recurrent, Rate of 40.5%; ③ the recurrence group CTR positive rate was 64.7%, non-recurrence group CTR positive rate was 92.6%, the difference was statistically significant (P <0.05); ④ calcitonin receptor in Jaffe Ⅰ, Ⅱ, Ⅲ The positive rates were 85.8%, 75.0% and 83.3% respectively, with no significant difference (P> 0.05). Conclusion The high expression of CTR in giant cell tumor of bone can help to evaluate the prognosis of giant cell tumor of bone.